[go: up one dir, main page]

WO2022260211A1 - Composition comprenant de l'extrait d'agastache rugosa et son utilisation pour l'amélioration de la fonction musculaire ou la prévention, le soulagement ou le traitement de maladies musculaires - Google Patents

Composition comprenant de l'extrait d'agastache rugosa et son utilisation pour l'amélioration de la fonction musculaire ou la prévention, le soulagement ou le traitement de maladies musculaires Download PDF

Info

Publication number
WO2022260211A1
WO2022260211A1 PCT/KR2021/010052 KR2021010052W WO2022260211A1 WO 2022260211 A1 WO2022260211 A1 WO 2022260211A1 KR 2021010052 W KR2021010052 W KR 2021010052W WO 2022260211 A1 WO2022260211 A1 WO 2022260211A1
Authority
WO
WIPO (PCT)
Prior art keywords
muscle
extract
baechohyang
improving
function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2021/010052
Other languages
English (en)
Korean (ko)
Inventor
권민선
최수영
윤원일
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cosmax NS Inc
Cosmax NBT Inc
Original Assignee
Cosmax NS Inc
Cosmax NBT Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cosmax NS Inc, Cosmax NBT Inc filed Critical Cosmax NS Inc
Publication of WO2022260211A1 publication Critical patent/WO2022260211A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/532—Agastache, e.g. giant hyssop
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Definitions

  • the present invention relates to a composition containing an extract of Baechohyang ( Agastache rugosa ) and its use for improving muscle function or preventing, improving or treating muscle disease, and more specifically, exhibits activity to increase muscle protein synthesis and / or inhibit muscle loss It provides a food composition for improving muscle function or preventing or improving muscle disease using a baechohyang extract, a health functional food composition, and/or a pharmaceutical composition for improving muscle function or preventing or treating muscle disease.
  • the present invention provides a method for improving muscle function or preventing, improving or treating muscle disease using an extract of baechohyang, and when preparing food or medicine for improving muscle function or preventing, improving or treating muscle disease, baechohyang ( Agastache rugosa ) extract provides the use of
  • Muscle atrophy is caused by a gradual decrease in muscle mass, and refers to muscle weakness and degeneration (Cell, 119(7): 907-910, 2004). Muscular atrophy is promoted by inactivity, oxidative stress, or chronic inflammation, and weakens muscle function and exercise capacity (Clinical Nutrition, 26(5): 524-534, 2007).
  • muscle mass which is maintained by the balance between muscle protein synthesis and breakdown. Muscular dystrophy occurs when protein degradation occurs more than synthesis (The International Journal of Biochemistry and Cell Biology, 37(10): 1985-1996, 2005).
  • Muscle size is regulated by intracellular signaling pathways that induce anabolism or catabolism within the muscle. Muscle protein synthesis is increased, which is indicated by an increase in muscle size (hypertrophy, muscle hypertrophy) or an increase in the number of muscle fibers (hyperplasia) due to increased muscle protein (The Korea Journal of Sports Science, 20(3): 1551-1561, 2011).
  • Muscle hypertrophy-inducing factors induce protein synthesis by phosphorylating downstream proteins based on stimulation of the PI3K (phosphatidylinositol-3 kinase)/Akt pathway in muscle cells.
  • PI3K phosphatidylinositol-3 kinase
  • Akt Akt pathway
  • Activation of mTOR can contribute to muscle mass increase by inducing muscle protein synthesis by activating two downstream targets, 4E-BP1 (4E-binding protein) and p70S6K (phosphorylated 70-kDa ribosomal S6 kinase) (The Korea Journal of Sports Science, 20(3): 1551-1561, 2011; The International Journal of Biochemistry and Cell Biology, 43(9): 1267-1276, 2011).
  • 4E-BP1 (4E-binding protein)
  • p70S6K phosphorylated 70-kDa ribosomal S6 kinase
  • Atrogin-1/MAFbx muscle atrophy F-box
  • MuRF-1 muscle RING-finger protein-1
  • Baechohyang Agastache rugosa
  • Agastache rugosa is a perennial herb that grows in the mountains and fields of East Asia, including Korea, Japan and China. , vomiting, bad breath, etc.
  • Korean Registered Patent No. 10-2160413 discloses the therapeutic effect of baechohyang on respiratory diseases
  • Korean Patent Publication No. 10-2019-0037036 discloses that baechohyang leaf extract enhances skin barrier function or skin
  • Baechohyang extract exhibits an effect of increasing muscle protein synthesis and/or inhibiting muscle loss by regulating various indicators involved in muscle protein synthesis or muscle loss, and completed the present invention.
  • an object of the present invention is to provide a composition for improving muscle function or preventing, improving or treating muscle diseases using the extract of Baechohyang.
  • Another object of the present invention is to provide a method for improving muscle function or preventing, improving or treating muscle diseases using the extract of Baechohyang.
  • Another object of the present invention is to provide the use of the extract of baechohyang in the preparation of food or medicine for improving muscle function or preventing, improving or treating muscle disease.
  • the present invention provides a food composition for muscle function improvement or muscle disease prevention or improvement containing the baechohyang extract.
  • the present invention provides a health functional food composition for improving muscle function or preventing or improving muscle disease, including the extract of baechohyang.
  • the present invention also provides a pharmaceutical composition for improving muscle function or preventing or treating muscle diseases, which includes an extract of Baechohyang.
  • the present invention provides a method for improving muscle function or preventing, improving or treating muscle disease, comprising administering an effective amount of an extract of Baechohyang to a subject in need thereof.
  • the present invention provides the use of the extract of baechohyang in the preparation of food or medicine for improving muscle function or preventing, improving or treating muscle disease.
  • the baechohyang extract may be extracted with water, C 1 to C 4 alcohol or a mixed solvent thereof.
  • the baechohyang extract may be a hot water extract or an ethanol extract.
  • the muscle disease may be a muscle disease caused by reduced muscle function, muscle wasting, or muscle degeneration.
  • the muscle disease is selected from the group consisting of atony, muscular atrophy, muscular dystrophy, myasthenia, cachexia and sarcopenia.
  • atony muscular atrophy
  • muscular dystrophy muscular dystrophy
  • myasthenia myasthenia
  • cachexia cachexia
  • sarcopenia can be one or more of the
  • the baechohyang extract may exhibit muscle protein synthesis increasing activity and / or muscle loss inhibitory activity.
  • the composition for improving muscle function or preventing, improving or treating muscle diseases including the extract of Baechohyang according to the present invention, is an E3 ubiquitin ligase factor involved in phosphorylation of mTOR protein involved in muscle protein synthesis and muscle loss.
  • Atrogin-1 and MuRF-1 muscle protein synthesis increases and/or muscle loss inhibitory activity is displayed, thereby improving muscle function and at the same time preventing, improving or It can be used effectively for treatment.
  • the composition of the present invention is safe for the human body by using extracts of natural materials as active ingredients and has few side effects, making it suitable for development of pharmaceuticals, quasi-drugs and health functional foods.
  • Figure 1 is a graph showing the change in p-mTOR activity level according to the treatment of Baechohyang extract in C2C12 muscle stem cells.
  • Figure 2 is a graph showing the change in Atrogin-1 mRNA expression level according to the treatment with the extract of Baechohyang in C2C12 muscle stem cells.
  • Figure 3 is a graph showing the change in MuRF1 mRNA expression level according to the treatment with Baechohyang extract in C2C12 muscle stem cells.
  • the extract of Baechohyang controls various indicators involved in muscle protein synthesis or muscle loss to synthesize muscle protein.
  • the present invention was completed by providing a composition for improving muscle function or preventing, improving, or treating muscle disease, including an extract of Baechohyang, confirming that it exhibits an increase and/or muscle loss inhibitory activity.
  • the first aspect of the present invention relates to a food composition for improving muscle function or preventing or improving muscle disease containing an extract of blackberry, and/or a health functional food composition for improving muscle function or preventing or improving muscle disease, including an extract of blackberry.
  • the baechohyang may be extracted from leaves, stems, flowers, roots, skins, fruits, or mixtures thereof.
  • an extract was prepared using aerial parts of baechohyang (aerial parts), that is, all parts except for the root, for example, stems, leaves, flowers and fruits as raw materials.
  • the baechohyang extract included as an active ingredient is an extract obtained by extraction of the baechohyang, a diluted or concentrated liquid of the extract, a dried product obtained by drying the extract, a crude product or a purified product of the extract, or It includes extracts of all formulations that can be formed using the extract itself and the extract, such as mixtures thereof.
  • the baechohyang extract of the present invention may be prepared and used in a dry powder form after extraction.
  • the baechohyang extract can be extracted from natural, hybrid or mutant plants of the plant, and can also be extracted from plant tissue culture.
  • Method for producing the extract of baechohyang of the present invention is not particularly limited, and may be prepared according to an extraction method commonly used in the art.
  • Non-limiting examples of the extraction method include hot water extraction, ultrasonic extraction, filtration, reflux extraction, immersion extraction, and the like, which may be performed alone or in combination with two or more methods.
  • the type of extraction solvent used for extracting baechohyang is not particularly limited, and any solvent known in the art may be used.
  • the extraction solvent include water; C 1 to C 4 lower alcohols such as methanol, ethanol, propyl alcohol and butyl alcohol; polyhydric alcohols such as glycerin, butylene glycol, and propylene glycol; and hydrocarbon solvents such as methyl acetate, ethyl acetate, acetone, benzene, hexane, diethyl ether, and dichloromethane; Or a mixture thereof may be used, and more preferably, baechohyang may be extracted with water (eg, hot water), C 1 to C 4 alcohol, or a mixed solvent thereof, but is not limited thereto.
  • the lower alcohol may be ethanol, more preferably 30% to 70%, and most preferably 40% to 60% ethanol, but is not limited thereto.
  • hot water or 40% to 60% ethanol was
  • the extract prepared according to the above method may be prepared into a powder through additional concentration and drying steps, if necessary.
  • Concentration is preferably performed using a vacuum concentrator or a vacuum rotary evaporator, but is not limited thereto.
  • drying is preferably reduced pressure drying, vacuum drying, boiling drying, spray drying or freeze drying, but is not limited thereto.
  • distilled water was treated with distilled water as an extraction solvent to the baechohyang from which foreign substances were removed by washing and drying, or extraction was performed by treating ethanol as an extraction solvent.
  • it was prepared into a powder through additional concentration and drying steps according to a method known in the art.
  • the term "muscular disease” is a muscle disease caused by muscle deterioration, muscle wasting or degeneration, and is preferably a disease reported in the art, specifically, atony, muscular atrophy , muscular dystrophy (muscular dystrophy), myasthenia, cachexia (cachexia), and may be any one or more selected from the group consisting of sarcopenia (sarcopenia), but is not limited thereto.
  • muscle wasting or degeneration occurs due to genetic factors, acquired factors, aging, etc., and muscle wasting is characterized by a gradual loss of muscle mass and weakening and degeneration of muscles, particularly skeletal or voluntary muscles and cardiac muscles.
  • mTOR protein when mTOR protein is phosphorylated and activated, it can induce the activation of proteins involved in muscle protein synthesis and muscle mass increase in the intracellular PI3K/Akt signaling pathway.
  • C2C12 muscle stem cells were treated with blackberry extract, and changes in the phosphorylation level of mTOR protein were analyzed. .
  • FIG. 1 it was confirmed that p-mTOR activity was increased by about 30% or more in the group treated with the hot water extract of Baechohyang compared to the untreated control group (CTL). Therefore, Baechohyang extract can be effectively used for the treatment of muscle diseases caused by muscle deterioration, muscle wasting, or muscle degeneration through its activity of increasing muscle protein synthesis.
  • Atrogin-1/MAFbx Muscle atrophy F-box
  • MuRF-1 Muscle RING-finger protein-1
  • muscle stem cells C2C12 are treated with dexamethasone to induce muscle loss, and then treated with black pepper extract
  • the changes in the mRNA expression levels of Atrogin-1 and MuRF-1 were analyzed.
  • the mRNA expression levels of Atrogin-1 and MuRF1 were significantly increased in the dexamethasone-treated group (CTL) compared to the untreated control group (NC), confirming that muscle loss was induced.
  • the baechohyang extract according to the present invention can be effectively used for the treatment of muscle diseases caused by muscle deterioration, muscle wasting or muscle degeneration through the activity of inhibiting muscle loss.
  • prevention refers to any action that suppresses or delays the progression of muscle diseases by administration of the composition of the present invention.
  • the term “improvement” means that the extent and/or undesirable clinical symptoms of a muscle disease state are reduced, or the time course of progression is slowed or lengthened.
  • muscle function refers to the ability to exert force by contraction of muscles, and muscle strength that can exert maximum contraction force to overcome resistance; muscular endurance, which is the ability of a muscle to contract and relax for a given weight for how long or how many times; and instantaneous power, which is the ability to exert strong force within a short period of time.
  • the muscle function is proportional to the amount of muscle, and the term “improvement of muscle function” means to improve muscle function decline due to muscle wasting or degeneration in a more positive direction.
  • the term “functional health food” includes both the meanings of “functional food” and “health food”.
  • the term "functional food” is the same term as food for special health use (FoSHU), and in addition to nutrient supply, medicine and medical effects processed to efficiently exhibit bioregulatory functions. Means high food.
  • health food refers to a food having an active health maintenance or promotion effect compared to general food
  • health supplement food refers to a food for health supplement purposes.
  • functional food, health food, and health supplement food are used interchangeably.
  • the food may be prepared in various forms such as tablets, capsules, powders, granules, liquids, and pills.
  • processed food with improved storage stability can be prepared by using the composition to modify the characteristics of agricultural products, livestock products, or aquatic products.
  • the health functional food composition of the present invention may also be prepared in the form of nutritional supplements and food additives, and is intended for consumption by humans or animals, including livestock.
  • Food compositions of this type can be prepared in various forms according to conventional methods known in the art.
  • General foods include, but are not limited to, beverages (including alcoholic beverages), fruits and their processed foods (e.g. canned fruits, bottled products, jams, marmalades, etc.), fish, meat and their processed foods (e.g. ham, sausages) Corned beef, etc.), breads and noodles (e.g. udon, buckwheat noodles, ramen, spagate, macaroni, etc.), fruit juice, various drinks, cookies, taffy, dairy products (e.g.
  • nutritional supplements are not limited thereto, but may be prepared by adding baechohyang extract to capsules, tablets, pills, etc.
  • the health functional food is not limited thereto, but, for example, the baechohyang extract is prepared in the form of tea, juice and drink, and can be consumed by liquefying, granulating, encapsulating and powdering so that it can be consumed (healthy drink) have.
  • the baechohyang extract in order to use the baechohyang extract in the form of a food additive, it may be prepared and used in the form of a powder or concentrate.
  • the baechohyang extract can be prepared in the form of a composition by mixing with known active ingredients known to be effective in improving muscle function and / or preventing, improving or treating muscle diseases.
  • the health beverage composition may contain various flavoring agents or natural carbohydrates as additional components, like conventional beverages.
  • the aforementioned natural carbohydrates include monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; polysaccharides such as dextrins and cyclodextrins; It may be a sugar alcohol such as xylitol, sorbitol, or erythritol.
  • Sweeteners include natural sweeteners such as thaumatin and stevia extract; Synthetic sweeteners such as saccharin and aspartame may be used.
  • the proportion of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the composition of the present invention.
  • Baechohyang extract may be contained as an active ingredient in a food composition for improving muscle function and/or preventing or improving muscle disease, the amount being effective in obtaining the above effect, for example, 0.01 to 100 weight relative to the total weight of the entire composition. % is preferred, but is not particularly limited thereto.
  • the health functional food of the present invention contains various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acids, protective colloidal thickeners, pH regulators, stabilizers, and preservatives. , glycerin, alcohol or carbonation agent, and the like.
  • the health food of the present invention may contain fruit flesh for producing natural fruit juice, fruit juice beverage, or vegetable beverage. These components may be used independently or in combination. The ratio of these additives is not very important, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
  • a second aspect of the present invention relates to a pharmaceutical composition for improving muscle function or preventing or treating muscle disease, including an extract of Baechohyang.
  • the description of the active ingredient, baechohyang extract and its effects are the same as those described in the first aspect, so the description thereof will be omitted.
  • treatment refers to all activities that improve or beneficially change muscle diseases by administration of the composition of the present invention.
  • the pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier may further include, for example, a carrier for oral administration or a carrier for parenteral administration.
  • Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid and the like.
  • Carriers for parenteral administration may include water, suitable oils, saline, aqueous glucose and glycols, and the like.
  • a stabilizer and a preservative may be further included. Suitable stabilizers include antioxidants such as sodium bisulfite, sodium sulfite or ascorbic acid.
  • Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol.
  • benzalkonium chloride methyl- or propyl-paraben and chlorobutanol.
  • the pharmaceutical composition of the present invention can be administered to mammals including humans by any method.
  • it can be administered orally or parenterally, and parenteral administration methods include, but are not limited to, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal , intranasal, enteral, topical, sublingual or rectal administration.
  • the pharmaceutical composition of the present invention may be formulated into a formulation for oral administration or parenteral administration according to the administration route as described above.
  • one or more buffers e.g., saline or PBS
  • carbohydrates e.g., glucose, mannose, sucrose, or dextran, etc.
  • antioxidants e.g., bacteriostatic agents, chelating agents (e.g., EDTA or glutathione), fillers, bulking agents, binders, adjuvants (eg aluminum hydroxide), suspending agents, thickening agents, wetting agents, disintegrating agents or surfactants, diluents or excipients.
  • chelating agents e.g., EDTA or glutathione
  • Solid preparations for oral administration include tablets, pills, powders, granules, solutions, gels, syrups, slurries, suspensions or capsules, etc., and these solid preparations include at least one excipient in the pharmaceutical composition of the present invention, for example , starch (including corn starch, wheat starch, rice starch, potato starch, etc.), calcium carbonate, sucrose, lactose, dextrose, sorbitol, mannitol, xylitol, erythritol maltitol, cellulose , methyl cellulose, sodium carboxymethyl cellulose and hydroxypropylmethyl-cellulose or gelatin may be mixed and prepared. Tablets or dragees may be obtained, for example, by combining the active ingredient with a solid excipient which is then milled and processed into a mixture of granules after adding suitable auxiliaries.
  • starch including corn starch, wheat starch, rice starch, potato starch, etc.
  • calcium carbonate suc
  • Liquid preparations for oral use include suspensions, solutions for oral use, emulsions, or syrups.
  • various excipients such as wetting agents, sweeteners, aromatics, or preservatives may be included. .
  • cross-linked polyvinylpyrrolidone, agar, alginic acid, or sodium alginate may be added as a disintegrant, and may further include anti-agglomerating agents, lubricants, wetting agents, flavoring agents, emulsifiers, and preservatives. .
  • the pharmaceutical composition of the present invention may be formulated according to a method known in the art in the form of injection, transdermal administration, and nasal inhalation with a suitable parenteral carrier.
  • a suitable parenteral carrier In the case of the injection, it must be sterilized and must be protected from contamination by microorganisms such as bacteria and fungi.
  • suitable carriers for injections include, but are not limited to, water, ethanol, polyols (eg, glycerol, propylene glycol, liquid polyethylene glycol, etc.), mixtures thereof, and/or solvents or dispersion media containing vegetable oils.
  • suitable carriers include Hanks' solution, Ringer's solution, phosphate buffered saline (PBS) with triethanolamine or isotonic solutions such as sterile water for injection, 10% ethanol, 40% propylene glycol and 5% dextrose. etc. can be used.
  • PBS phosphate buffered saline
  • isotonic solutions such as sterile water for injection, 10% ethanol, 40% propylene glycol and 5% dextrose. etc.
  • various antibacterial and antifungal agents such as paraben, chlorobutanol, phenol, sorbic acid, and thimerosal may be further included.
  • the injection may further include an isotonic agent such as sugar or sodium chloride.
  • Transdermal preparations include ointments, creams, lotions, gels, external solutions, pastas, liniments, air rolls, and the like.
  • 'transdermal administration' means that an effective amount of the active ingredient contained in the pharmaceutical composition is delivered into the skin by topically administering the pharmaceutical composition to the skin.
  • the compounds used according to the present invention may be administered in pressurized packs or with a suitable propellant, for example dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. It can be conveniently delivered in the form of an aerosol spray from a nebulizer. In the case of pressurized aerosols, dosage units may be determined by providing a valve that delivers a metered amount.
  • gelatin capsules and cartridges for use in inhalers or insufflators may be formulated to contain a powder mixture of the compound and a suitable powder base such as lactose or starch. Formulations for parenteral administration are described in all pharmaceutical chemistry generally known prescriptions, Remington's Pharmaceutical Science, 15th Edition, 1975. Mack Publishing Company, Easton, Pennsylvania 18042, Chapter 87: Blaug, Seymour.
  • the pharmaceutical composition of the present invention can provide a desirable effect of improving muscle function and/or improving exercise performance when containing an effective amount of the extract of Baechohyang.
  • the term "effective amount” refers to an amount that exhibits a response greater than that of the negative control, preferably an amount sufficient to improve muscle function and/or prevent, ameliorate, or treat muscle disease by increasing muscle protein or inhibiting muscle loss. says Baechohyang extract in the pharmaceutical composition of the present invention may be included in an amount of 0.01 to 99.9%, the remaining amount may be occupied by a pharmaceutically acceptable carrier.
  • the effective amount of the baechohyang extract contained in the pharmaceutical composition of the present invention will vary depending on the form in which the composition is commercialized.
  • the total effective amount of the pharmaceutical composition of the present invention can be administered to the patient in a single dose, or by a fractionated treatment protocol in which multiple doses are administered over a long period of time.
  • the pharmaceutical composition of the present invention may vary the content of the active ingredient according to the condition of the patient. For example, it may be divided into 1 to several times to be administered in an amount of preferably 0.001 to 100 mg, more preferably 0.01 to 10 mg per 1 kg of body weight per day based on the baechohyang extract.
  • the dosage of the baechohyang extract is determined by considering various factors such as the patient's age, weight, health condition, sex, severity of disease, diet and excretion rate, as well as the route of administration of the pharmaceutical composition and the number of treatments.
  • the pharmaceutical composition according to the present invention is not particularly limited in its formulation, administration route and administration method as long as it exhibits the effects of the present invention.
  • a third aspect of the present invention relates to a quasi-drug composition for improving muscle function and/or preventing or improving muscle disease, which includes an extract of blackberry.
  • the description of the active ingredient, the extract of baechohyang, and its effects are the same as those described in the first aspect, so the description thereof will be omitted.
  • the term "quasi-drugs” refers to textiles, rubber products or similar products used for the purpose of treating, mitigating, treating or preventing diseases of humans or animals, products that have weak effects on the human body or do not directly act on the human body, and devices or non-machines and similar items, products falling under one of the agents used for sterilization, insecticidal, and similar purposes to prevent infectious diseases, for the purpose of diagnosing, treating, mitigating, treating, or preventing human or animal diseases It may refer to items other than instruments, machines or devices among items used and items other than instruments, machines or devices among items used for the purpose of pharmacologically affecting the structure and function of humans or animals.
  • the quasi-drug may include external skin preparations and personal hygiene products. Preferably, it may be a disinfectant cleanser, shower foam, gargreen, wet tissue, detergent, soap, hand wash, or ointment, but is not limited thereto.
  • the composition according to the present invention when used as a quasi-drug additive, the composition may be added as it is or used together with other quasi-drugs or quasi-drug ingredients, and may be appropriately used according to a conventional method.
  • the mixing amount of the active ingredient may be appropriately determined depending on the purpose of use.
  • a fourth aspect of the present invention provides a method for improving muscle function or preventing, improving or treating muscle disease, comprising administering an effective amount of an extract of Baechohyang to a subject in need thereof.
  • the term "administration" means providing a composition of the present invention to a subject by any suitable method.
  • the term "individual” used in the present invention includes, but is not limited to, mammals including humans.
  • the preferred dosage of the composition of the present invention varies depending on the condition and body weight of the subject, the degree of fatigue, the formulation form of the extract of Baechohyang extract, etc., but may be appropriately selected to achieve the intended effect of improving muscle function or preventing, improving or treating muscle diseases.
  • the term "effective amount” refers to phosphorylation of mTOR protein involved in muscle protein synthesis and E3 ubiquitin ligase factors involved in muscle loss, Atrogin-1 and MuRF-1, by regulating muscle protein It refers to an amount of Baechohyang extract sufficient to improve muscle function by exhibiting synthesis increase and/or muscle loss inhibitory activity, or to prevent, improve, or treat muscle diseases caused by muscle decline, muscle wasting, or muscle degeneration.
  • the baechohyang extract of the present invention may be administered once or repeatedly several times at regular time intervals.
  • the composition containing the Baechohyang extract may be administered to a subject by various routes, preferably orally.
  • it can be used alone or in combination with other methods to improve muscle function or prevent, improve, or treat muscle diseases.
  • a fifth aspect of the present invention provides the use of the extract of baechohyang in the preparation of food or medicine for improving muscle function or preventing, improving or treating muscle disease.
  • the food may be a health functional food, and the description of the characteristics and effects of the baechohyang extract is the same as described above, so the description is omitted.
  • baechohyang alcohol extract 100 g was put in 1.5 l of 50% alcohol and extracted at 70 ° C. for 4 hours. The extracted sample was filtered under reduced pressure with Whatman No. 2 filter paper, and the filtered extract was concentrated with a vacuum rotary evaporator and then dried to prepare a baechohyang alcohol extract.
  • C2C12 cells (ATCC ® CRL-1772TM), which are muscle stem cells, were cultured in DMEM medium containing 10% rFBS, 100 U/ml penicillin, and 100 ⁇ g/ml streptomycin at 37°C and 5% CO2. Cells were placed in a 6-well plate at 2 x 10 5 cells/well and cultured for 24 hours. After 24 hours, the medium was exchanged with DMEM medium containing 2% HS, 100 U/ml penicillin, and 100 ⁇ g/ml streptomycin, and differentiated under 37°C and 5% CO2 conditions for 5 days.
  • Example 1-1 After 5 days, 2% HS, 100 U/ml penicillin, and 100 ug/ml streptococci were added to the hot water extract of Example 1-1 and the alcohol extract of Example 1-2 to concentrations of 100 ug/ml and 200 ug/ml, respectively. After treatment in DMEM medium containing mycin, cultured for 24 hours. After removing the medium and washing with PBS, p-mTOR activity was measured using a p-mTOR (phospho-mTOR) ELISA kit (Cell signaling, #7976C).
  • p-mTOR activity was increased by about 30% or more in the group treated with the hot water extract of Baechohyang compared to the untreated control group (CTL). Therefore, Baechohyang extract can be effectively used for the treatment of muscle diseases caused by muscle deterioration, muscle wasting, or muscle degeneration through its activity of increasing muscle protein synthesis.
  • C2C12 cells (ATCC ® CRL-1772 Model) were cultured in DMEM medium containing 10% rFBS, 100 U/ml penicillin, and 100 ⁇ g/ml streptomycin at 37°C and 5% CO 2 conditions. Cells were placed in a 6-well plate at 2 x 10 5 cells/well and cultured for 24 hours.
  • the prepared cells were divided into 6 groups, treated with DMEM medium containing 2% HS, 100 U/ml of penicillin, and 100 ⁇ g/ml of streptomycin as shown in Table 1, and cultured for 72 hours.
  • Real-time PCR was performed using AccuPower 2X Greenstar qPCR Master mix (Cat No. K-6254). Primer sequences used in PCR are shown in Table 2 below.
  • the mRNA expression levels of Atrogin-1 and MuRF1 were significantly increased in the dexamethasone-treated group (CTL) compared to the untreated control group (NC), confirming that muscle loss was induced.
  • CTL dexamethasone-treated group
  • NC untreated control group
  • the expression levels of Atrogin-1 and MuRF1 mRNAs increased by dexamethasone were significantly reduced according to the treatment with the extract of the herbaceous herb. Therefore, Baechohyang extract can be effectively used for the treatment of muscle diseases caused by muscle deterioration, muscle wasting, or muscle degeneration through the activity of inhibiting muscle loss.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition comprenant un extrait d'Agastache rugosa, et son utilisation pour l'amélioration de la fonction musculaire ou la prévention, le soulagement ou le traitement de maladies musculaires. Plus spécifiquement, la présente invention concerne : une composition alimentaire pour améliorer la fonction musculaire ou prévenir ou soulager une maladie musculaire; une composition alimentaire fonctionnelle de santé; et/ou une composition pharmaceutique pour l'amélioration de la fonction musculaire ou la prévention ou le traitement de maladies musculaires, un extrait d'Agastache rugosa présentant l'activité d'augmentation de la synthèse des protéines musculaires et/ou d'inhibition de la perte musculaire. De plus, la présente invention concerne un procédé d'amélioration de la fonction musculaire ou de prévention, de soulagement, ou de traitement de maladies musculaires à l'aide d'un extrait d'Agastache rugosa, et concerne une utilisation d'un extrait d'Agastache rugosa dans la préparation d'un aliment ou d'un médicament destiné à améliorer la fonction musculaire ou à prévenir, soulager ou traiter des maladies musculaires.
PCT/KR2021/010052 2021-06-10 2021-08-02 Composition comprenant de l'extrait d'agastache rugosa et son utilisation pour l'amélioration de la fonction musculaire ou la prévention, le soulagement ou le traitement de maladies musculaires Ceased WO2022260211A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2021-0075750 2021-06-10
KR20210075750 2021-06-10

Publications (1)

Publication Number Publication Date
WO2022260211A1 true WO2022260211A1 (fr) 2022-12-15

Family

ID=84425245

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/010052 Ceased WO2022260211A1 (fr) 2021-06-10 2021-08-02 Composition comprenant de l'extrait d'agastache rugosa et son utilisation pour l'amélioration de la fonction musculaire ou la prévention, le soulagement ou le traitement de maladies musculaires

Country Status (1)

Country Link
WO (1) WO2022260211A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040064485A (ko) * 2003-01-13 2004-07-19 (주) 김형민한약연구소 아세틸콜린에스터라제 저해 생약 조성물
KR101805801B1 (ko) * 2017-05-12 2017-12-13 경희대학교 산학협력단 틸리아닌을 유효성분으로 포함하는 파킨슨 질환의 예방 또는 치료용 약학적 조성물
KR20200049437A (ko) * 2019-01-23 2020-05-08 (주)뉴트리 동부, 잠두 또는 제비콩을 함유하는 근 기능 개선 또는 운동수행능력 향상용 조성물
KR102167238B1 (ko) * 2019-05-23 2020-10-19 한국한의학연구원 곽향 추출물을 유효성분으로 함유하는 파골세포 억제용 조성물 및 이의 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040064485A (ko) * 2003-01-13 2004-07-19 (주) 김형민한약연구소 아세틸콜린에스터라제 저해 생약 조성물
KR101805801B1 (ko) * 2017-05-12 2017-12-13 경희대학교 산학협력단 틸리아닌을 유효성분으로 포함하는 파킨슨 질환의 예방 또는 치료용 약학적 조성물
KR20200049437A (ko) * 2019-01-23 2020-05-08 (주)뉴트리 동부, 잠두 또는 제비콩을 함유하는 근 기능 개선 또는 운동수행능력 향상용 조성물
KR102167238B1 (ko) * 2019-05-23 2020-10-19 한국한의학연구원 곽향 추출물을 유효성분으로 함유하는 파골세포 억제용 조성물 및 이의 용도

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "NewMed-Korea Institute of Science and Technology, Signed Patent Technology Transfer Agreement", WOW TV = KOREA ECONOMY TV, KOREA BUSINESS NEWS, KOREA, Korea, pages 1 - 1, XP009542840, Retrieved from the Internet <URL:https://www.wowtv.co.kr/NewsCenter/News/Read?articleId=A202012090092> *

Similar Documents

Publication Publication Date Title
US8853261B2 (en) Nutraceutical composition from Garcinia mangostana
KR102447966B1 (ko) 녹용 유산균 발효물을 유효성분으로 포함하는 근육 질환 또는 근육 손상의 예방, 개선 또는 치료용 조성물
WO2014084572A1 (fr) Agent améliorant la biodisponibilité de la catéchine comprenant de la cyclodextrine
WO2010140734A1 (fr) Composition, pour la prévention ou le traitement d&#39;affections liées à l&#39;obésité et médiées par l&#39;activation d&#39;ampk, et dont les principes actifs dont des lignanes de 2,5-bis-aryl-3,4-diméthyltétrahydrofurane
US6531148B1 (en) Therapeutic agents
KR101088069B1 (ko) 판두라틴 유도체 또는 이를 함유하는 카엠페리아 판두라타 추출물의 신규한 용도
KR102267195B1 (ko) 균주 배양액으로부터 분리된 활성 물질을 포함하는 피부 개선용 조성물
KR102124986B1 (ko) 익모초 추출물 또는 레오누린을 함유하는 근육 질환 예방 또는 치료용 또는 근 기능 개선용 조성물
WO2019098811A2 (fr) Composition pour prévenir, soulager ou traiter des maladies de perte osseuse, comprenant cyclo(his-pro) (chp)
KR20220113912A (ko) 피마자 추출물을 유효성분으로 포함하는 근육 질환 예방, 개선 또는 치료용 조성물
KR101851167B1 (ko) 조팝나무 추출물을 유효성분으로 함유하는 알러지성 질환의 예방 및 치료용 약학적 조성물
JP5905874B2 (ja) パンドラチン誘導体又はボエセンベルギアパンドラター抽出物の筋肉増加促進、抗疲労及び運動遂行能力向上に関する新たな用途
KR20150010923A (ko) 키레놀 또는 희첨 추출물을 포함하는 골다공증 예방, 개선 또는 치료용 조성물
WO2022260211A1 (fr) Composition comprenant de l&#39;extrait d&#39;agastache rugosa et son utilisation pour l&#39;amélioration de la fonction musculaire ou la prévention, le soulagement ou le traitement de maladies musculaires
EP1416927B1 (fr) Derives sesquiterpenoides dotes d&#39;un effet inhibiteur sur la differenciation des adipocytes
KR102217264B1 (ko) 코디움 속 해조류 추출물을 유효성분으로 포함하는 근육 질환 예방, 개선 또는 치료용 조성물
KR102524071B1 (ko) 한약재 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물
WO2023249392A1 (fr) Composition pour la prévention, l&#39;atténuation ou le traitement d&#39;une infection à coronavirus, contenant un extrait d&#39;herbe médicinale utilisé en tant que principe actif
WO2023204602A1 (fr) Composition pour la prévention, l&#39;atténuation ou le traitement d&#39;une infection à coronavirus, comprenant un extrait de complexe d&#39;herbes médicinales en tant que principe actif
KR102746020B1 (ko) 약쑥을 함유하는 근육 질환 예방 및 치료용 또는 근 기능 개선용 조성물
KR20180053014A (ko) 조팝나무, 배나무, 뱀무의 혼합 추출물을 유효성분으로 함유하는 알러지성 질환의 예방 및 치료용 약학적 조성물
WO2019225845A1 (fr) Composition pour soulager le méningiome en utilisant le salidroside et la bétuline
KR102818485B1 (ko) 한약재 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물
KR102645399B1 (ko) 유스카픽 에시드를 포함하는 근 기능 개선 또는 근육 질환 예방, 개선 또는 치료용 조성물
WO2015122728A1 (fr) Composition anti-tuberculose pour le traitement et la prévention de la tuberculose comprenant un extrait ou de melia azedarach l. ou un extrait de lobelia chinensis lour et des fractions de ceux-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21945278

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21945278

Country of ref document: EP

Kind code of ref document: A1